# Atara Biotherapeutics

Source: https://onco.cc/companies/atara-biotherapeutics/  
OnCo record `atara-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Atara Biotherapeutics is the Californian company behind Ebvallo, the first approved off-the-shelf T-cell therapy, which treats Epstein-Barr virus lymphoma after transplant using T cells from healthy donors.

## Summary

Atara Biotherapeutics develops allogeneic Epstein-Barr virus-specific T-cell therapies. Tabelecleucel (Ebvallo), made from banked donor T cells matched by HLA, was approved in the European Union in December 2022 and by the FDA in 2025 for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease; Pierre Fabre holds worldwide commercial rights. Atara's EBV-targeted CAR-T programme ATA3219 for lymphoma and lupus was paused in 2025 as the company restructured.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Atara Biotherapeutics, Inc.; NASDAQ:ATRA
- Tags: drug-maker
- HQ: Thousand Oaks, California
- Type: cell-therapy
- Website: https://www.atarabio.com/
- Ticker: NASDAQ:ATRA

## Sources

- Official website: https://www.atarabio.com/

## Connected records

- drugs: [Tabelecleucel](https://onco.cc/drugs/tabelecleucel/)

---
JSON: https://onco.cc/api/v1/entities/atara-biotherapeutics.json